Oncotarget
ALT associates with the ATRX alterations and the I-A signature. A representative image of a grade III astrocytoma section that was positive for both ALT and for p53 nuclear staining is shown in Figure 3 of Jiao et al. The dynamic range of the image was digitally altered for the July cover of Oncotarget. See Jiao et al.
Mutations in circulating mitochondrial DNA: Cassandra of oral cancer? |
https://doi.org/10.18632/oncotarget.567 Eugene S. Kandel |
664-665 |
PDF | HTML | How to cite | Order a Reprint |
Engineering Enzymatically Activated “Molecular Grenades” for Cancer |
https://doi.org/10.18632/oncotarget.562 Samuel R. Denmeade, and John T. Isaacs |
666-667 |
PDF | HTML | How to cite | Order a Reprint |
Folate Receptor Alpha: A New Tool in the Diagnosis and Treatment of Lung Cancer |
https://doi.org/10.18632/oncotarget.575 Laura D. Wood |
668-669 |
PDF | HTML | How to cite | Order a Reprint |
Circulating tumor-derived mutant mitochondrial DNA: a predictive biomarker of clinical prognosis in human squamous cell carcinoma. |
https://doi.org/10.18632/oncotarget.523 Katsuhiro Uzawa, Takao Baba, Fumihiko Uchida, Masanobu Yamatoji, Atsushi Kasamatsu, Yosuke Sakamoto, Katsunori Ogawara, Masashi Shiiba, Hiroki Bukawa, and Hideki Tanzawa |
670-677 |
Abstract | PDF | HTML | Supplementary Information | How to cite | Order a Reprint |
A thymidylate synthase ternary complex-specific antibody, FTS, permits functional monitoring of fluoropyrimidines dosing |
https://doi.org/10.18632/oncotarget.554 Kalpesh Patel, Sashidhar R. Yerram, Nilofer A. Azad, and Scott E. Kern |
678-685 |
Abstract | PDF | HTML | How to cite | Order a Reprint |
Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 (AEZS-108) |
https://doi.org/10.18632/oncotarget.546 Karoly Szepeshazi, Andrew V Schally, Gunhild Keller, Norman L Block, Daniel Benten, Gabor Halmos, Luca Szalontay, Irving Vidaurre, Miklos Jaszberenyi, and Ferenc G Rick |
686-699 |
Abstract | PDF | HTML | Supplementary Information | How to cite | Order a Reprint |
The response to PAK1 inhibitor IPA3 distinguishes between cancer cells with mutations in BRAF and Ras oncogenes |
https://doi.org/10.18632/oncotarget.587 Ruchi Singhal, and Eugene S. Kandel |
700-708 |
Abstract | PDF | HTML | How to cite | Order a Reprint |
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas |
https://doi.org/10.18632/oncotarget.588 Yuchen Jiao, Patrick J. Killela, Zachary J. Reitman, B.Ahmed Rasheed, Christopher M. Heaphy, Roeland F. de Wilde, Fausto J. Rodriguez, Sergio Rosemberg, Sueli Meiko Obashinjo, Suely Kazue Nagahashi Marie, Chetan Bettegowda, Nishant Agrawal, Eric Lipp, Christopher Pirozzi, Giselle Lopez, Yiping He, Henry Friedman, Allan H. Friedman, Gregory J. Riggins, Matthias Holdhoff, Peter Burger, Roger McLendon, Darell D. Bigner, Bert Vogelstein, Alan K. Meeker, Kenneth W. Kinzler, Nickolas Papadopoulos, Luis A. Diaz, Jr., and Hai Yan |
709-722 |
Abstract | PDF | HTML | Supplementary Information | How to cite | Order a Reprint |
NEDD9, a novel target of miR-145, increases the invasiveness of glioblastoma |
https://doi.org/10.18632/oncotarget.547 Maria Carmela Speranza, Véronique Frattini, Federica Pisati, Dimos Kapetis, Paola Porrati, Marica Eoli, Serena Pellegatta, and Gaetano Finocchiaro |
723-734 |
Abstract | PDF | HTML | Supplementary Information | How to cite | Order a Reprint |
Copyright © 2021 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC